Biotech Industry – Zacks Analyst Interviews
Zacks Market Commentaries (June 1st, 2009) Writes:
The Biotech industry as a whole continues to underperform the market so far this year. As of May 26, 2009, Both the AMEX Biotech Index and the broader NASDAQ Biotech Index declined 6.8% (AMEX Biotech has 20 biotech companies while NASDAQ Biotech Index includes over 130 component companies), while the Dow Jones Biotech Index declined 3% (which includes 33 companies).
At the same time, both the NASDAQ Composite and S&P 500 have achieved positive returns. NASDAQ has made a gain of 11% as of 5/26/09 and the S&P 500 has gained 0.8%, while the Dow Jones Industrials reached a negative 3.5% return.
This constitutes a sharp contrast with last year when the Biotech industry as a whole achieved much better performance than the market. In 2008, all three biotech indices outperformed all three major market indices by a large margin. The three major indices declined as much as over 40% (34%, 41%
...16x;, 1Q09;, 3sbio Inc, AMAG Pharmaceuticals Inc.;, April, Bayer HealthCare;, Biotech Industry - Zacks;, cancer, Canon DC230 1MP DVD Camcorder with 35x Optical Zoom;, Celera Group;, Cell Therapeutics Inc., Dow 30, Dow Biotech;, Dow Jones Biotech;, Fda, Genta Inc.;, kidney cancer, Liver Cancer, Market Commentary, MYGN;, NASDAQ biotech, Nasdaq Composite, Nexavar, Onyx Pharmaceuticals Inc, Prostate Cancer, Provenge;, S, Stocks to Watch, SurModics Inc., treatment of prostate cancer, USD, Yahoo, Zacks Market Commentaries


![[Most Recent Quotes from www.kitco.com]](http://www.kitconet.com/charts/metals/gold/t24_au_en_usoz_2.gif)
![[Most Recent Quotes from www.kitco.com]](http://www.kitconet.com/charts/metals/silver/t24_ag_en_usoz_2.gif)
